MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ
3.930
-0.060
-1.50%
Closed 16:10 11/19 EST
OPEN
3.965
PREV CLOSE
3.990
HIGH
4.050
LOW
3.910
VOLUME
291.34K
TURNOVER
0
52 WEEK HIGH
6.45
52 WEEK LOW
2.920
MARKET CAP
315.60M
P/E (TTM)
-2.0046
1D
5D
1M
3M
1Y
5Y
1D
Atea Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $8
Benzinga · 3d ago
Atea Pharmaceuticals price target raised to $8 from $7 at Morgan Stanley
TipRanks · 3d ago
Weekly Report: what happened at AVIR last week (1109-1113)?
Weekly Report · 4d ago
Atea Pharmaceuticals Earnings Call Highlights HCV Momentum
TipRanks · 5d ago
Atea Pharmaceuticals: A Clean DDI Profile And Shorter Treatment Duration Threaten Current Market Leaders
Seeking Alpha · 6d ago
Atea Q3 Loss Narrows On Lower Expenses; Hepatitis C Trial Data Due In Early 2027
NASDAQ · 11/10 14:37
Atea Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial Results and Enters Credit Facility of Up to $200 Million
NASDAQ · 11/10 03:31
More
About AVIR
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Its product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which has the potential to improve the current standard of care (SOC) for the treatment of patients with hepatitis C virus (HCV) infection and AT-587 which has the potential to be the first direct-acting antiviral (DAA) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (HEV) infection. The global HCV Phase III program it is conducting consists of two randomized, open-label studies: C-BEYOND which has clinical trial sites in the United States and Canada, and C-FORWARD which has clinical trial sites in countries outside of North America. AT-587 has demonstrated potent nanomolar antiviral activity against HEV in vitro.

Webull offers Atea Pharmaceuticals Inc stock information, including NASDAQ: AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.